H.C. Wainwright downgrades Talaris Therapeutics to Neutral

  • Investing.com
H.C. Wainwright downgrades Talaris Therapeutics to Neutral

A H.C. Wainwright analyst downgraded Talaris Therapeutics (NASDAQ: TALS) from Buy to Neutral with a price target of $No data.

Prior to this rating, Talaris Therapeutics had 3 buy ratings, 2 hold ratings, and 0 sell ratings.

For consensus analyst estimates and price targets on Talaris Therapeutics, click here. For more news on Talaris Therapeutics, click here.

Talaris Therapeutics's stock price closed at $1.94. They are up 0% in the last month and down -78.91% in the last 12 months.

According to Investing Pro, Talaris Therapeutics's fair value is $2.56, an upside of 31.90%. Talaris Therapeutics's fair value comes with a high degree of uncertainty, according to InvestingPro.

Check out Talaris Therapeutics's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100